bd@krishbiotech.com +91 33 2582-4472

Overview

An overview:

  • KBRPL has expanded their horizons by initiating the drug discovery efforts in areas that have scientific and commercial promise: Metabolic Disorders, Oncology,Immunology, Pain and Inflammation.
  • The research model would focus both on acquiring new assets from other organizations /Institutes as well as out-licensing existing in-house portfolios.
  • KBRPL in-licensed two programs from Piramal Enterprises Ltd., Mumbai, namely RoR-gamma t antagonist (for autoimmune disorders) and GPR120 agonists (for diabetes and metabolic disorders).
  • The state-of-the art, R & D centre is situated in Kalyani, a well-connected town on the outskirts of Kolkata.
  • KBRPL has 5 molecules in various stages of discovery to preclinical development
  • Several collaborative research programs have been signed with premier government institutes like Indian Institute of Technology, Roorkee, National Institute of Technology, Durgapur etc.
  • 
Download Brochure
  • Career
  • Feedback
T-1, QK-17 (Part) WBIIDC, Phase III,
Kalyani, Nadia, West Bengal 741 235 ,INDIA

+91 33 2582-4472